179 related articles for article (PubMed ID: 36822077)
1. Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.
Tarantini F; Cumbo C; Zagaria A; Anelli L; Parciante E; Redavid I; Coccaro N; Tota G; Conserva MR; Minervini CF; Minervini A; Attolico I; Russo Rossi A; Specchia G; Musto P; Albano F
Leuk Res; 2023 Apr; 127():107023. PubMed ID: 36822077
[TBL] [Abstract][Full Text] [Related]
2. Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events.
Sant'Antonio E; Camerini C; Rizzo V; Musolino C; Allegra A
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):573-579. PubMed ID: 34078586
[TBL] [Abstract][Full Text] [Related]
3. [Influence of clonal hematopoiesis on non-hematological diseases and aging processes].
Rieger MA
Inn Med (Heidelb); 2022 Nov; 63(11):1115-1125. PubMed ID: 36214849
[TBL] [Abstract][Full Text] [Related]
4. Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis but facilitates termination of emergency (stress) granulopoiesis.
Williams O; Hu L; Huang W; Patel P; Bartom ET; Bei L; Hjort E; Hijiya C; Eklund EA
J Biol Chem; 2023 Jul; 299(7):104867. PubMed ID: 37247756
[TBL] [Abstract][Full Text] [Related]
5. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
6. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG
Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757
[No Abstract] [Full Text] [Related]
7. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
[TBL] [Abstract][Full Text] [Related]
8. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Verma D; Kantarjian H; Shan J; O'Brien S; Estrov Z; Garcia-Manero G; Koller C; Borthakur G; Cortes J
Cancer; 2010 Jun; 116(11):2673-81. PubMed ID: 20499401
[TBL] [Abstract][Full Text] [Related]
10. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
Lenaerts T; Pacheco JM; Traulsen A; Dingli D
Haematologica; 2010 Jun; 95(6):900-7. PubMed ID: 20007137
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
[TBL] [Abstract][Full Text] [Related]
13. Somatic mosaicism in chronic myeloid leukemia in remission.
Mitani K; Nagata Y; Sasaki K; Yoshida K; Chiba K; Tanaka H; Shiraishi Y; Miyano S; Makishima H; Nakamura Y; Nakamura Y; Ichikawa M; Ogawa S
Blood; 2016 Dec; 128(24):2863-2866. PubMed ID: 27784671
[No Abstract] [Full Text] [Related]
14. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Fabarius A; Haferlach C; Müller MC; Erben P; Lahaye T; Giehl M; Frank O; Seifarth W; Hehlmann R; Hochhaus A
Haematologica; 2007 Jun; 92(6):834-7. PubMed ID: 17550857
[TBL] [Abstract][Full Text] [Related]
16. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
17. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N
Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008
[No Abstract] [Full Text] [Related]
18. [Practical management of side effects of tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
Mezei G; Illés Á; Batár P
Orv Hetil; 2021 Jul; 162(30):1198-1207. PubMed ID: 34304154
[TBL] [Abstract][Full Text] [Related]
19. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
